ANI Pharmaceuticals, Inc.
ANIP
$63.26
$1.863.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 190.57M | 148.33M | 138.04M | 137.43M | 131.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.57M | 148.33M | 138.04M | 137.43M | 131.65M |
| Cost of Revenue | 80.28M | 63.08M | 57.70M | 49.16M | 53.42M |
| Gross Profit | 110.29M | 85.26M | 80.34M | 88.27M | 78.23M |
| SG&A Expenses | 69.52M | 70.28M | 49.42M | 48.02M | 44.46M |
| Depreciation & Amortization | 22.60M | 15.75M | 14.70M | 14.69M | 15.19M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.05M | 159.23M | 129.11M | 122.38M | 122.94M |
| Operating Income | 1.53M | -10.89M | 8.93M | 15.06M | 8.71M |
| Income Before Tax | -13.76M | -31.50M | -2.29M | 25.34M | 947.00K |
| Income Tax Expenses | -3.49M | -7.33M | 0.00 | 7.13M | -208.00K |
| Earnings from Continuing Operations | -10.28M | -24.17M | -2.29M | 18.21M | 1.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.28M | -24.17M | -2.29M | 18.21M | 1.16M |
| EBIT | 1.53M | -10.89M | 8.93M | 15.06M | 8.71M |
| EBITDA | 24.13M | 4.85M | 23.63M | 29.74M | 23.91M |
| EPS Basic | -0.55 | -1.27 | -0.05 | 0.84 | 0.04 |
| Normalized Basic EPS | -0.19 | -0.51 | 0.14 | 0.34 | 0.10 |
| EPS Diluted | -0.55 | -1.27 | -0.05 | 0.83 | 0.04 |
| Normalized Diluted EPS | -0.19 | -0.51 | 0.14 | 0.34 | 0.10 |
| Average Basic Shares Outstanding | 19.45M | 19.40M | 19.32M | 19.10M | 19.00M |
| Average Diluted Shares Outstanding | 19.45M | 19.40M | 19.32M | 19.42M | 19.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -3.95% | -1.68% | -17.80% | 2.23% | 35.15% |
